Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
10.1111/iju.14111 10 BertramM
The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes
10.1242/dev.008441 49
Scientists are perplexed, but they are not shocked
US$ 23.65
US$ 22.40
US$ 20.52
US$ 25.11
US$ 29.75
